Safety will be key in Abbott's new autoimmune partnership
This article was originally published in Scrip
Executive Summary
Abbott's latest partnership, with Biotest of Germany, provides a welcome boost to the group's immunology pipeline, but it will need to tread carefully if it is to avoid the pitfalls that have felled other programmes in the field. One of these is the question of safety.